• Je něco špatně v tomto záznamu ?

Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century

F. Tichanek, A. Försti, A. Hemminki, O. Hemminki, K. Hemminki

. 2023 ; 15 (10) : . [pub] 20230516

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23009758

Grantová podpora
grant No 856620 (Chaperon) the European Union's Horizon 2020 research and innovation programme
ID Project No. LX22NPO5102 The Swedish Research Council, Jane and Aatos Erkko Foundation, Sigrid Juselius Foundation, Finnish Cancer Organizations, University of Helsinki, Helsinki University Central Hospital, Novo Nordisk Foundation, Päivikki and Sakari Sohlberg Foundation, Finnis

Kidney and bladder cancers share etiology and relatively good recent survival, but long-term studies are rare. We analyzed survival for these cancers in Denmark, Finland, Norway (NO), and Sweden (SE) over a 50-year period (1971-2020). Relative 1- and 5-year survival data were obtained from the NORDCAN database, and we additionally calculated conditional 5/1-year survival. In 2016-2020, 5-year survivals for male kidney (79.0%) and bladder (81.6%) cancers were best in SE. For female kidney cancer, NO survival reached 80.0%, and for bladder cancer, SE survival reached 76.1%. The magnitude of 5-year survival improvements during the 50-year period in kidney cancer was over 40% units; for bladder cancer, the improvement was over 20% units. Survival in bladder cancer was worse for women than for men, particularly in year 1. In both cancers, deaths in the first year were approximately as many as in the subsequent 4 years. We could document an impressive development for kidney cancer with tripled male and doubled female 5-year survival in 50 years. Additionally, for bladder cancer, a steady improvement was recorded. The current challenges are to curb early mortality and target treatment to reduce long-term mortality.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23009758
003      
CZ-PrNML
005      
20230721095453.0
007      
ta
008      
230707s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers15102782 $2 doi
035    __
$a (PubMed)37345119
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Tichanek, Filip $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 30605 Pilsen, Czech Republic $u Institute of Pathological Physiology, Faculty of Medicine in Pilsen, Charles University, 32300 Pilsen, Czech Republic
245    10
$a Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century / $c F. Tichanek, A. Försti, A. Hemminki, O. Hemminki, K. Hemminki
520    9_
$a Kidney and bladder cancers share etiology and relatively good recent survival, but long-term studies are rare. We analyzed survival for these cancers in Denmark, Finland, Norway (NO), and Sweden (SE) over a 50-year period (1971-2020). Relative 1- and 5-year survival data were obtained from the NORDCAN database, and we additionally calculated conditional 5/1-year survival. In 2016-2020, 5-year survivals for male kidney (79.0%) and bladder (81.6%) cancers were best in SE. For female kidney cancer, NO survival reached 80.0%, and for bladder cancer, SE survival reached 76.1%. The magnitude of 5-year survival improvements during the 50-year period in kidney cancer was over 40% units; for bladder cancer, the improvement was over 20% units. Survival in bladder cancer was worse for women than for men, particularly in year 1. In both cancers, deaths in the first year were approximately as many as in the subsequent 4 years. We could document an impressive development for kidney cancer with tripled male and doubled female 5-year survival in 50 years. Additionally, for bladder cancer, a steady improvement was recorded. The current challenges are to curb early mortality and target treatment to reduce long-term mortality.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Försti, Asta $u Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany $1 https://orcid.org/0000000298574728
700    1_
$a Hemminki, Akseli $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, 00290 Helsinki, Finland $u Comprehensive Cancer Center, Helsinki University Hospital, 00290 Helsinki, Finland $1 https://orcid.org/0000000171038530
700    1_
$a Hemminki, Otto $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, 00290 Helsinki, Finland $u Department of Urology, Helsinki University Hospital, 00290 Helsinki, Finland
700    1_
$a Hemminki, Kari $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 30605 Pilsen, Czech Republic $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, Germany $1 https://orcid.org/0000000227693316 $7 mzk20201092711
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 15, č. 10 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37345119 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230707 $b ABA008
991    __
$a 20230721095447 $b ABA008
999    __
$a ok $b bmc $g 1958491 $s 1196022
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 15 $c 10 $e 20230516 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a grant No 856620 (Chaperon) $p the European Union's Horizon 2020 research and innovation programme
GRA    __
$a ID Project No. LX22NPO5102 $p The Swedish Research Council, Jane and Aatos Erkko Foundation, Sigrid Juselius Foundation, Finnish Cancer Organizations, University of Helsinki, Helsinki University Central Hospital, Novo Nordisk Foundation, Päivikki and Sakari Sohlberg Foundation, Finnis
LZP    __
$a Pubmed-20230707

Najít záznam

Citační ukazatele

Možnosti archivace